Breaking News Instant updates and real-time market news.

NVRO

Nevro

$44.05

-16.04 (-26.69%)

, BSX

Boston Scientific

$33.56

-0.16 (-0.47%)

07:25
07/25/18
07/25
07:25
07/25/18
07:25

Nevro weakness a buying opportunity, says Canaccord

Canaccord analyst Jason Mills said the weakness in Nevro (NVRO) following a summary judgment announced yesterday in its patent dispute with Boston Scientific (BSX) is a buying opportunity. The analyst said the move yesterday priced in a worst-case scenario, implying Nevro will lose all IP protection over its HF-10kHz technology, but he believes the current situation is more nuanced and the ultimate outcomes remain fluid. He believes the market overreacted and he recommends investors buy the weakness. Mills reiterated his Buy rating and $80 price target on Nevro shares.

NVRO

Nevro

$44.05

-16.04 (-26.69%)

BSX

Boston Scientific

$33.56

-0.16 (-0.47%)

  • 25

    Jul

  • 02

    Aug

  • 14

    Aug

  • 15

    Aug

  • 27

    Aug

NVRO Nevro
$44.05

-16.04 (-26.69%)

07/17/18
JPMS
07/17/18
NO CHANGE
Target $77
JPMS
Overweight
Nevro valuation attractive after recent selloff, says JPMorgan
JPMorgan analyst Robbie Marcus says Nevro's better than expected preannounced Q2 results were overshadowed by lowered 2018 guidance. While Nevro's near-term outlook will be challenged amid internal rep hiring headwinds and increasing competitive pressures, the bar has been reset at current valuation levels, Marcus tells investors in a research note titled "Down But Not Out; Reiterate OW Rating On Lowered Expectations And Attractive Valuation." The analyst sees see upside from current levels and reiterates an Overweight rating on Nevro. He lowered his price target for the shares to $77 from $98.
07/17/18
WBLR
07/17/18
NO CHANGE
WBLR
Outperform
Nevro risk/reward favorable at current levels, says William Blair
William Blair analyst Margaret Kaczor believes Nevro's lowered 2018 outlook reset expectations and gives the company room to meet or exceed estimates going forward. She does not see a change in the underlying long-term business dynamics. The stock's risk/reward is favorable and Nevro's "strong" clinical and product pipeline and brand in the marketplace has value that is not fully reflected in the stock at these levels, Kaczor tells investors in a research note. She keeps an Outperform rating on the shares.
07/17/18
LEER
07/17/18
NO CHANGE
Target $90
LEER
Outperform
Nevro price target lowered to $90 from $95 at Leerink
Leerink analyst Danielle Antalffy lowered her price target for Nevro to $90 from $95, while reiterating an Outperform rating on the shares. The analyst acknowledges that given the execution issues over the past 18 months, management is in "the penalty box." But Antalffy also believes that Nevro's story remains intact from a fundamental perspective, as Spinal Cord Stimulation is a sustainable double-digit growth market for the foreseeable future, with further acceleration possible as new indications come online, and Nevro has a highly differentiated product with what she views as still the best-in-class clinical data to support it. The risk/reward is now much more favorable, she contends.
07/25/18
JPMS
07/25/18
NO CHANGE
Target $77
JPMS
Overweight
Nevro selloff yesterday a 'clear buying opportunity,' says JPMorgan
JPMorgan analyst Robbie Marcus views yesterday's selloff in shares of Nevro (NVRO) as a "clear buying opportunity." The headlines suggest Boston Scientific (BSX) was the clear winner in the summary judgment, but the "nuance in the actual ruling swings this in favor of Nevro," Marcus tells investors in a research note. The analyst's interpretation is that while Boston doesn't infringe Nevro's three remaining patents with its current trials and U.S. commercialized tonic stimulation devices, the ruling implies that any attempt to actually commercialize a high-frequency device in the U.S. remains an infringement of Nevro's remaining patents '102 and '472. While Nevro's systems claims patents were ruled invalid, the company's broader method claim patents were upheld, Marcus writes. He keeps an Overweight rating on Nevro with a $77 price target. The stock closed yesterday down 26%, or $15.78, to $44.22.
BSX Boston Scientific
$33.56

-0.16 (-0.47%)

07/11/18
JPMS
07/11/18
NO CHANGE
JPMS
Overweight
JPMorgan more positive on Nevro positioning in legal fight after management talk
JPMorgan analyst Robert Marcus said that after his talks with Nevro's (NVRO) management team he is more positive on the company's positioning in its ongoing legal fight against Boston Scientific (BSX). Headlines regarding a tentative ruling that supported invalidating 5 of the 7 patents at issue, which he attributes for Nevro's decline yesterday, masked that the judge favored Nevro on the two remaining patents and the company only needs to successfully defend one of its patents to keep Boston Scientific out of the market, Marcus tells investors. He maintains an Overweight rating on Nevro shares.
07/23/18
RBCM
07/23/18
NO CHANGE
Target $36
RBCM
Top Pick
Boston Scientific price target raised to $36 from $32 at RBC Capital
RBC Capital analyst Glenn Novarro raised his price target on Boston Scientific to $36 and kept his Top Pick rating ahead of its Q2 earnings, saying it is "one of the elite growth companies in large-cap MedTech" with a possibility of being an acquisition target, warranting its premium valuation. The analyst notes however that after a 36% year-to-date run-up in the stock price, operational revenue growth closer to the high end of the forecast 5%-7% growth rate and a FY18 guidance increase are needed to move the stock price higher in the short term.
07/23/18
RHCO
07/23/18
NO CHANGE
Target $39
RHCO
Buy
Boston Scientific price target raised to $39 from $34 at SunTrust
SunTrust analyst Bruce Nudell raised his price target on Boston Scientific (BSX) to $39 and kept his Buy rating ahead of its Q2 results, saying that based on the pipeline and market opportunities discussed at the recent Endoscopy analyst meeting, a higher long-term assumption for the sector is warranted. Nudell expects the management to discuss the recent speculation about a proposed acquisition offer by Stryker (SYK), the U.S. Watchman momentum, and the opportunity of other products like Spectra WaveWriter, Vercise, Resonate w/HeartLogic, ACURATE, and the EP portfolio inclusive of DirectSense.

TODAY'S FREE FLY STORIES

HOG

Harley-Davidson

$34.25

-0.62 (-1.78%)

09:28
07/23/19
07/23
09:28
07/23/19
09:28
Hot Stocks
Harley-Davidson continues to see FY19 annual cash savings of $25M-$30M »

Sees FY20 annual cash…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

MRNS

Marinus Pharmaceuticals

$3.99

0.11 (2.84%)

09:28
07/23/19
07/23
09:28
07/23/19
09:28
Hot Stocks
Breaking Hot Stocks news story on Marinus Pharmaceuticals »

Marinus drops 66% to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FITB

Fifth Third

$27.84

-0.11 (-0.39%)

09:25
07/23/19
07/23
09:25
07/23/19
09:25
Hot Stocks
Fifth Third says it continues to see a generally healthy economic backdrop »

Says wants to leverage…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 29

    Aug

BIDU

Baidu

$111.74

-0.5 (-0.45%)

09:25
07/23/19
07/23
09:25
07/23/19
09:25
Downgrade
Baidu rating change  »

Baidu downgraded to Mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

PLCE

Children's Place

$91.41

-7.96 (-8.01%)

09:24
07/23/19
07/23
09:24
07/23/19
09:24
Recommendations
Children's Place analyst commentary at DA Davidson »

Children's Place…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

LTS

Ladenburg Thalmann

$2.97

0.03 (1.02%)

, COWN

Cowen Group

$15.87

-0.23 (-1.43%)

09:23
07/23/19
07/23
09:23
07/23/19
09:23
Conference/Events
National Cannabis Industry Association to hold a summit »

Cannabis Business Summit…

LTS

Ladenburg Thalmann

$2.97

0.03 (1.02%)

COWN

Cowen Group

$15.87

-0.23 (-1.43%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

MORN

Morningstar

$153.65

-0.5 (-0.32%)

, NTRS

Northern Trust

$92.76

-0.09 (-0.10%)

09:21
07/23/19
07/23
09:21
07/23/19
09:21
Conference/Events
CFA Institute to hold a seminar »

CFA Institute Seminar for…

MORN

Morningstar

$153.65

-0.5 (-0.32%)

NTRS

Northern Trust

$92.76

-0.09 (-0.10%)

JPM

JPMorgan

$114.31

0.77 (0.68%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 24

    Jul

  • 01

    Aug

  • 06

    Aug

ZG

Zillow

$47.20

0.36 (0.77%)

, Z

Zillow

$47.41

0.27 (0.57%)

09:20
07/23/19
07/23
09:20
07/23/19
09:20
Recommendations
Zillow, Zillow, Realogy, Amazon.com analyst commentary at Craig-Hallum »

Zillow weakness on…

ZG

Zillow

$47.20

0.36 (0.77%)

Z

Zillow

$47.41

0.27 (0.57%)

RLGY

Realogy

$5.17

-0.08 (-1.52%)

AMZN

Amazon.com

$1,985.93

21.15 (1.08%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 07

    Aug

  • 07

    Aug

  • 08

    Aug

TRPX

Therapix Biosciences

$2.32

-0.02 (-0.85%)

09:20
07/23/19
07/23
09:20
07/23/19
09:20
Hot Stocks
Breaking Hot Stocks news story on Therapix Biosciences »

Therapix Biosciences…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

09:18
07/23/19
07/23
09:18
07/23/19
09:18
Options
Overnight activity included 219 trades in SPX and 6 trades in VIX »

219 trades were executed…

SPX

S&P 500

$0.00

(0.00%)

VIX

Volatility Index S&P 500 Options

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TWTR

Twitter

$37.58

0.81 (2.20%)

09:17
07/23/19
07/23
09:17
07/23/19
09:17
Recommendations
Twitter analyst commentary at BMO Capital »

Twitter's delayed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jul

  • 30

    Jul

REAL

RealReal

$24.84

0.69 (2.86%)

09:17
07/23/19
07/23
09:17
07/23/19
09:17
Initiation
RealReal initiated at BofA/Merrill »

RealReal initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Aug

TECH

Bio-Techne

$208.62

-0.61 (-0.29%)

09:17
07/23/19
07/23
09:17
07/23/19
09:17
Hot Stocks
Bio-Techne and Uman Diagnostic announce agreement »

Uman Diagnostics, now…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

  • 13

    Nov

ATEC

Alphatec

$4.60

0.1 (2.22%)

09:16
07/23/19
07/23
09:16
07/23/19
09:16
Hot Stocks
Alphatec announces commercial launch of InVictus spinal fixation platform »

Alphatec Holdings…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 12

    Sep

AMRH

AMERI Holdings

$0.34

-0.0098 (-2.80%)

, GOOG

Alphabet

$1,138.09

8.09 (0.72%)

09:15
07/23/19
07/23
09:15
07/23/19
09:15
Hot Stocks
AMERI Holdings advances Google partnership »

AMERI Holdings (AMRH)…

AMRH

AMERI Holdings

$0.34

-0.0098 (-2.80%)

GOOG

Alphabet

$1,138.09

8.09 (0.72%)

GOOGL

Alphabet Class A

$1,139.52

7.85 (0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 25

    Jul

  • 03

    Aug

  • 08

    Aug

  • 27

    Oct

09:15
07/23/19
07/23
09:15
07/23/19
09:15
General news
U.S. FHFA Home Price index rose 0.1% to 275.0 in May »

U.S. FHFA Home Price…

FCBP

First Choice Bank

$22.80

0.03 (0.13%)

09:14
07/23/19
07/23
09:14
07/23/19
09:14
Earnings
First Choice Bank announces Q1 EPS 58c, one est. 54c »

"Our larger scale…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDNS

Cadence Design

$72.68

-0.21 (-0.29%)

09:12
07/23/19
07/23
09:12
07/23/19
09:12
Recommendations
Cadence Design analyst commentary at DA Davidson »

Cadence Design price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YVR

Liquid Media

$1.65

(0.00%)

09:11
07/23/19
07/23
09:11
07/23/19
09:11
Hot Stocks
Liquid Media says 'confident' Gaming Division is 'positioned for success' »

Liquid Media Group…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KO

Coca-Cola

$51.25

-0.15 (-0.29%)

09:10
07/23/19
07/23
09:10
07/23/19
09:10
Hot Stocks
Coca-Cola CEO says Powerade has not had good start to the year »

Says Dasani has faced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 19

    Sep

WMT

Walmart

$112.80

-1.11 (-0.97%)

09:09
07/23/19
07/23
09:09
07/23/19
09:09
Recommendations
Walmart analyst commentary at Loop Capital »

Walmart price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Aug

  • 25

    Sep

  • 13

    Nov

CONE

CyrusOne

$58.69

0.48 (0.82%)

09:08
07/23/19
07/23
09:08
07/23/19
09:08
Hot Stocks
CyrusOne promotes Bill Williams to CIO »

CyrusOne announced it has…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Aug

BIDU

Baidu

$111.74

-0.5 (-0.45%)

09:07
07/23/19
07/23
09:07
07/23/19
09:07
Downgrade
Baidu rating change at OTR Global »

Baidu downgraded to Mixed…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Aug

CECE

CECO Environmental

$8.88

0.01 (0.11%)

09:06
07/23/19
07/23
09:06
07/23/19
09:06
Hot Stocks
CECO Environmental announces important new order »

CECO Environmental…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Aug

  • 06

    Aug

SPY

SPDR S&P 500 ETF Trust

$297.82

0.65 (0.22%)

, SPX

S&P 500

$0.00

(0.00%)

09:06
07/23/19
07/23
09:06
07/23/19
09:06
General news
IMF lowers 2019 global growth forecast to 3.2%, 2020 growth view to 3.5% »

The IMF announced that…

SPY

SPDR S&P 500 ETF Trust

$297.82

0.65 (0.22%)

SPX

S&P 500

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.